Cargando…
Roxithromycin treatment inhibits TGF-β1-induced activation of ERK and AKT and down-regulation of Caveolin-1 in rat airway smooth muscle cells
BACKGROUND: Roxithromycin (RXM) has been widely used in asthma treatment; however, the mechanism has not been fully understood. The aim of our study was to investigate the underlying mechanism of RXM treatment in mediating the effect of transforming growth factor (TGF)-β1 on airway smooth muscle cel...
Autores principales: | Dai, Yuanrong, Li, Fengqin, Wu, Liqin, Wang, Ruili, Li, Ping, Yan, Sunshun, Xu, Hui, Xia, Mengling, Bai, Chunxue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256937/ https://www.ncbi.nlm.nih.gov/pubmed/25109503 http://dx.doi.org/10.1186/s12931-014-0096-z |
Ejemplares similares
-
Roxithromycin-Associated Acute Thrombocytopenia
por: Rossi, Marco, et al.
Publicado: (2021) -
Caveolin-1 is required for contractile phenotype expression by airway smooth muscle cells
por: Gosens, Reinoud, et al.
Publicado: (2011) -
Roxithromycin attenuates inflammation via modulation of RAGE-influenced calprotectin expression in a neutrophilic asthma model
por: Gu, Xiaofei, et al.
Publicado: (2021) -
SMAD-Independent Down-Regulation of Caveolin-1 by TGF-β: Effects on Proliferation and Survival of Myofibroblasts
por: Sanders, Yan Y., et al.
Publicado: (2015) -
Effect of Low-Dose, Long-Term Roxithromycin on Airway Inflammation and Remodeling of Stable Noncystic Fibrosis Bronchiectasis
por: Liu, Jifeng, et al.
Publicado: (2014)